Omprakash Tanwar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3751444/publications.pdf

Version: 2024-02-01

840776 794594 19 714 11 19 citations h-index g-index papers 19 19 19 1261 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Ethyl Pyruvate as a Potential Defense Intervention against Cytokine Storm in COVID-19?. ACS Omega, 2021, 6, 7754-7760.	3.5	5
2	Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents. Bioorganic and Medicinal Chemistry, 2019, 27, 1421-1429.	3.0	13
3	Pyrazole-pyrazoline as promising novel antimalarial agents: A mechanistic study. European Journal of Medicinal Chemistry, 2018, 149, 139-147.	5.5	65
4	Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents. Bioorganic Chemistry, 2018, 80, 319-333.	4.1	21
5	Synthesis and antimalarial activity of quinoline-substituted furanone derivatives and their identification as selective falcipain-2 inhibitors. Medicinal Chemistry Research, 2015, 24, 879-890.	2.4	16
6	Pharmacophore based virtual screening, synthesis and SAR of novel inhibitors of Mycobacterium sulfotransferase. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 701-707.	2.2	8
7	Synthesis, 3D-QSAR and docking studies of pyrimidine nitrile-pyrazoline: a novel class of hybrid antimalarial agents. Medicinal Chemistry Research, 2015, 24, 1018-1037.	2.4	16
8	Novel hydrazine derivatives as selective DPP-IV inhibitors: findings from virtual screening and validation through molecular dynamics simulations. Journal of Molecular Modeling, 2014, 20, 2118.	1.8	11
9	Synthesis and biological evaluation of some new pyrazoline substituted benzenesulfonylurea/thiourea derivatives as anti-hyperglycaemic agents and aldose reductase inhibitors. European Journal of Medicinal Chemistry, 2014, 80, 209-217.	5.5	24
10	Structure based virtual screening of MDPI database: Discovery of structurally diverse and novel DPP-IV inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3447-3451.	2.2	18
11	3D quantitative structure–activity relationship for quinoline, benzimidazole and benzofuran-based analogs as phosphodiesterases IV (PDE-IV) inhibitors. Medicinal Chemistry Research, 2013, 22, 5153-5166.	2.4	2
12	Quinoline: A versatile heterocyclic. Saudi Pharmaceutical Journal, 2013, 21, 1-12.	2.7	330
13	Identification of ZINC02765569: a potent inhibitor of PTP1B by vHTS. Medicinal Chemistry Research, 2013, 22, 28-34.	2.4	15
14	Pharmacophore model generation and 3D-QSAR analysis of N-acyl and N-aroylpyrazolines for enzymatic and cellular B-Raf kinase inhibition. Medicinal Chemistry Research, 2013, 22, 2174-2187.	2.4	6
15	Pyrazolines: A Biological Review. Mini-Reviews in Medicinal Chemistry, 2013, 13, 921-931.	2.4	123
16	Recent Updates on Biological Activities of Oxadiazoles. Mini-Reviews in Medicinal Chemistry, 2013, 13, 1027-1046.	2.4	25
17	Modeling VEGFR kinase inhibition of aminopyrazolopyridine urea derivatives using topological and physicochemical descriptors: a quantitative structure activity analysis study. Medicinal Chemistry Research, 2012, 21, 3958-3964.	2.4	3
18	3D-QSAR of amino-substituted pyrido [3,2B] pyrazinones as PDE-5 inhibitors. Medicinal Chemistry Research, 2012, 21, 202-211.	2.4	8

#	Article	IF	CITATIONS
19	2-D QSAR studies of steroidal natural products oleanic acid and their semisynthetic derivatives as potent protein tyrosine phosphatase 1B inhibitors. Medicinal Chemistry Research, 2012, 21, 351-361.	2.4	5